Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Dementia01:30

Dementia

503
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
503
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

782
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
782

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Miro1 mutations disrupt cellular calcium homeostasis via dysregulation of mitochondria-ER-contact-sites, rendering iPSC-derived neurons more susceptible to lipid peroxidation.

Neurobiology of disease·2026
Same author

Cognitive and Neuroimaging Divergence Between Juvenile and Adult FUS Amyotrophic Lateral Sclerosis.

Annals of clinical and translational neurology·2026
Same author

Innate immune signaling as a potential pathomechanistic biomarker for distinct subtypes in amyotrophic lateral sclerosis.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same author

VAPB confers selective neuroprotection by driving autophagic degradation of pathogenic aggregates in ALS.

Acta neuropathologica communications·2026
Same author

Alzheimer's Disease Co-Pathology and Cognitive Impairment in Amyotrophic Lateral Sclerosis.

Annals of neurology·2026
Same author

Impact of Partial- to Full-Support Escalation With Microaxial Flow Pumps Prior to Durable Left Ventricular Assist Device Implantation.

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery·2026

相关实验视频

Updated: Jan 11, 2026

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.7K

一个无监督的XAI框架用于痴呆症检测,并进行上下文丰富.

Devesh Singh1,2, Yusuf Brima3, Fedor Levin3

  • 1German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany. devesh.singh@med.uni-rostock.de.

Scientific reports
|November 12, 2025
PubMed
概括

可解释的人工智能 (XAI) 方法改善了对痴呆症诊断的脑图像分析. 将神经解剖学特征与人工智能相关性地图相结合,提高了对人工智能决策支持系统的透明度和临床信任.

关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.大脑体积测量 大脑体积测量可解释的人工智能 (XAI)在前性痴呆症.磁共振成像技术 磁共振成像技术神经退行性疾病的神经退行性疾病定性评价 定性评价 定性评价

更多相关视频

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
08:43

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment

Published on: August 7, 2017

8.4K
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.9K

相关实验视频

Last Updated: Jan 11, 2026

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.7K
Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
08:43

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment

Published on: August 7, 2017

8.4K
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.9K

科学领域:

  • 神经成像和人工智能的人工智能
  • 临床决策支持系统 临床决策支持系统
  • 生物医学信息学 生物医学信息学

背景情况:

  • 可解释的人工智能 (XAI) 提高了对临床决策支持人工智能预测的信任.
  • 对XAI解释质量的有限验证阻碍了临床采用.
  • 卷积神经网络 (CNN) 用于大脑成像分析,但需要可解释的输出.

研究的目的:

  • 通过将神经解剖学特征与CNN相关性地图集成,引入评估痴呆症研究中XAI方法的框架.
  • 评估不同XAI解释策略对疾病分类准确性和临床有效性的影响.
  • 改进XAI解释空间,以提高AI驱动的诊断工具的透明度.

主要方法:

  • 从六个队伍 (N=3253) 的脑部MRI扫描中训练了一个CNN,涵盖正常认知,轻度认知障碍,阿尔茨海默病和前性痴呆.
  • 集成的神经解剖学形态特征与CNN相关性地图进行分类.
  • 实施和评估了三种后期的XAI方法:模型简化,逐例解释和文本解释.
  • 使用形态特征作为基本真理和临床医生的定性评估进行了集群分析.

主要成果:

  • 以形态丰富的解释空间改善了集群的同质性和完整性.
  • 模型简化解释区分转换器和稳定参与者.
  • 每个例子的解释建议了认知轨迹,而文本解释提供了基于规则的发现.
  • 临床医生评估确定了XAI在临床实践中的挑战和机遇.

结论:

  • 开发的框架完善了XAI解释空间和生成方法,用于在痴呆症研究中基于AI的决策支持.
  • XAI方法在提高神经退行性疾病的诊断效率和对人工智能系统的临床信任方面表现有前途.
  • 将神经解剖学特征与AI相关性地图集成,为验证XAI质量提供了一个强大的方法.